Take the 2-minute tour ×
Ask Patents is a question and answer site for people interested in improving and participating in the patent system. It's 100% free, no registration required.

The McKinsey report "Personalized medicine - the path forward" states that laboratory-developed diagnostics tests (LDTs) are somehow immune to patent challenges.

Quote: "Dx [diagnostics] companies with approved tests cannot protect their IP under the current regulatory system and CLIA governance. Lab service providers can provide substitutes to the FDA-approved Dx tests without fear of patent challenges..." (p. 33 of http://www.mckinsey.com/~/media/mckinsey/dotcom/client_service/Pharma%20and%20Medical%20Products/PMP%20NEW/PDFs/McKinsey%20on%20Personalized%20Medicine%20March%202013.ashx)

Can anyone explain to me whether this is true, and why?

share|improve this question
    
Welcome to ask patents -- please check our help pages for what kind of questions and how to ask -- patents.stackexchange.com/help –  Soren Aug 21 at 17:14

Your Answer

 
discard

By posting your answer, you agree to the privacy policy and terms of service.

Browse other questions tagged or ask your own question.